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Previewsto fully understand how neural tissue
changes in the minutes and hours after
learning. Thus, molecular and optical
imaging are perhaps most suited to
understand how these compartments
change in the living organism.
The present work, along with previous
studies (Blumenfeld-Katzir et al., 2011;
Lerch et al., 2011) combining imaging
and histology, provides valuable insights
into the types of structural changes
that can be detected on different time-
scales with noninvasive MRI. For in-
stance, 5 days of training in the water
maze task increased the volume of the
hippocampus, as measured with MRI,
and produced a correlated increase in
GAP-43, a marker for neuronal process
remodeling (Lerch et al., 2011). In another
study using 5 days of training with the
same task, changes in diffusion MRI
parameters were related to increases in
GFAP, synaptophysin, and myelin basic
protein (MBP) (Blumenfeld-Katzir et al.,
2011). The time frame of these studies
allows for slower remodeling mecha-
nisms like dendritric sprouting or glio-
genesis to occur (Figure 1). Such mecha-
nisms could contribute to the structural1060 Neuron 73, March 22, 2012 ª2012 Elsebrain changes detected using MRI in
humans with long-term learning (Dragan-
ski et al., 2004; Scholz et al., 2009).
Sagi and colleagues0 results provide
us with an important reminder that the
brain is an extremely dynamic structure.
This study used a focused period of
video game playing, but presumably
many of the learning experiences we
undergo throughout our lives produce
similar effects in task-relevant regions of
our brains. The findings therefore have
more general implications for human neu-
roimaging. Many studies that employ the
standard imaging methods used here
assume that human brain structure is rela-
tively static, at least on short timescales.
However, we must remember that we
are merely looking at snapshots of an
organ that is in a constant state of flux,
and these new findings demonstrate that
even the relatively crude technique of
MRI is sensitive to this rapid structural
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In this issue of Neuron, Raj et al. (2012) and Zhou et al. (2012) use graph theory to suggest that neurodegen-
erative diseases spread diffusively via intrinsic brain networks. These studies provide a powerful model for
understanding and predicting disease-specific profiles of neurodegeneration.
Open access under CC BY license.Neurodegenerative brain diseases are
collectively characterized by two core
features: abnormal protein deposition
and distinctive profiles of damage across
the brain and over time (Frisoni et al.,
2010; Rohrer et al., 2011). If we under-stood in detail how proteinopathies
translate to clinical phenotypes, we might
anticipate and perhaps prevent the
devastating impact of these diseases.
While we have recognized for some
time that spatiotemporal brain atrophyprofiles track neuropathological patterns
of disease evolution (Frisoni et al., 2010),
we have lacked a principled framework
for understanding and predicting the
profiles observed. The brain is composed
of neural networks and graph theory
Figure 1. From Syndromes to Molecular Nexopathies
The figure attempts to reconcile the transneuronal model of network degener-
ation suggested by the data of Raj et al. (2012) and Zhou et al. (2012) with
empirical data on distinctive brain atrophy profiles associated with specific
genetic proteinopathies (e.g., Rohrer et al., 2011). In the central brain
schematic, circles represent local network elements and lines represent
transneuronal anatomical connections (these need not correspond closely to
the ‘‘edges’’ of graph theoretical representations: Zhou et al., 2012). The
effects of proteinopathies (colored) on intrinsic network architecture (gray)
in the frontal (FL), temporal (TL), and parietal (PL) lobes in each cerebral
hemisphere are shown. The side panels show coronal (left) and axial (right)
brain MRI sections representing typical atrophy profiles produced by muta-
tions in the microtubule-associated protein tau gene (MAPT: relatively
symmetrical, relatively localized anterior temporal and inferior frontal atrophy)
and the progranulin gene (GRN: strongly asymmetric fronto-temporo-parietal
atrophy). Behavioral variant frontotemporal dementia was the presenting
syndrome in each case. Initial involvement of an epicenter (ep) in right orbito-
frontal cortex propagates over common transneuronal pathways in the target
network (green); we hypothesize that, in addition, MAPT mutations may
preferentially damage shorter anatomical pathways within the target network
(dark blue) and connected off-target network elements (light blue), while
GRN mutations may preferentially damage longer intrahemispheric pathways
within the target network (red) and connected off-target pathways (magenta)
via a catastrophic reamplification process. This modulation of the basic diffu-
sive template for network disintegration anticipates the distinctive atrophy
profiles observed.
Neuron
Previewsprovides a methodology for
representing and analyzing
those networks (Bullmore
and Sporns, 2009). Work in
animal models has demon-
strated a correspondence
between mathematically
derived network characteris-
tics and the hierarchical
and distributed architectures
of neuroanatomy (Modha
and Singh, 2010). Network-
level analysis is an ideal
approach to understanding
neurodegenerative diseases,
due both to the fundamentally
coherent and distributed
nature of the underlying path-
ological processes and the
failure of conventional ap-
proaches to adequately ex-
plain the distinctive phenom-
enology of these diseases.
However, the potential clin-
ical value of network-based
approaches remains largely
unrealized.
Two papers in this issue of
Neuron (Raj et al., 2012;
Zhou et al., 2012) take us
further toward this goal, by
applying the methods of
graph theory to quantify and
predict network disintegra-
tion in a range of neurodegen-
erative diseases. Thesepapers capitalize on two key recent
insights: the expression of neurodegen-
eration within specific, distributed, in-
trinsic brain networks (Zhou et al., 2010)
and the propensity of culprit proteins to
‘‘template’’ further protein aggregation
and spread of disease along neural path-
ways (Hardy, 2005; de Calignon et al.,
2012). Raj et al. (2012) model network
diffusion based on tractography data in
the healthy brain and derive robust spatial
eigenmodes that correspond closely to
atrophy profiles observed in Alzheimer’s
disease and frontotemporal dementia;
their model makes no prior assumptions
about selective neuronal vulnerabilities
or protein-specific factors. Zhou et al.
(2012) show that common neurode-
generation syndromes seed distinctive
connectivity structures derived using
task-free fMRI in the healthy brain: their
data suggest that the neurodegenerativeprocess spreads primarily between
neurons according to the functional prox-
imity of specific brain regions acting as
critical hub-like ‘‘epicenters,’’ rather than
various alternative candidate mecha-
nisms. Both papers agree that trans-
synaptic diffusion plays a core role in
the spread of neurodegenerative path-
ologies, and together they provide
a succinct framework for characteriz-
ing network disintegration in these
diseases.
For clinical neurologists and molecular
biologists, these elegant and sophisti-
cated studies hold a strong intuitive
appeal. That being said, the studies raise
as many issues as they resolve. So where
do we go from here? Viewed critically,
these two studies are directed chiefly
toward the ‘‘deep phenotyping’’ of neuro-
degenerative syndromes: the mapping
between clinical profiles and permissiveNeuron 73, March 22, 2brain architectures. Less
widely pursued has been the
reverse mapping, from spe-
cific molecular pathologies
via network breakdown to
clinical disease; yet accurate
prediction and tracking of
molecular pathology from
phenotype will be essential
for the rational application
of specific protein-targeting
therapies. As Raj et al. (2012)
and Zhou et al. (2012) point
out, large-scale connectivity
approaches have yet to settle
such fundamental issues as
the basis for initial targeting
of particular brain regions by
neurodegenerative patholo-
gies, the role of protein-speci-
fic mechanisms in disease
evolution and (perhaps most
problematically of all) the typi-
cally wide variation in pheno-
typic expression among indi-
viduals with a particular
molecular diagnosis. On the
other hand, we already know
that particular canonical
syndromes can be produced
by genetic mutations with
radically different group-level
brain atrophy profiles (Rohrer
et al., 2011; see Figure 1). A
complete network account
of neurodegeneration willneed to resolve such apparently paradox-
ical observations. In our view, progress is
likely to depend on incorporating molec-
ular pathological ‘‘minutiae’’ (Raj et al.,
2012) into existing network models.
One way forward may be to assess
patterns of network breakdown that
segregate according to the morphology
of network elements rather than net-
works in their neuroanatomical entirety.
The idea that particular network compo-
nents may be differentially vulnerable to
neuropathological processes is implicit
in the work of Zhou et al. (2012) and com-
patible with the results of Raj et al. (2012).
Intrinsic brain connectivity and trans-
synaptic disease spread may be over-
arching principles, while within damaged
networks, proteinopathies may operate
via subsidiary mechanisms such as
those delineated by Zhou et al. (2012) to
produce specific profiles of network012 ª2012 Elsevier Inc. 1061
Neuron
Previewsbreakdown. Recent rapid progress in
characterizing genetic and histopatholog-
ical substrates of the frontotemporal
dementias has enabled, for the first time,
a more or less complete analysis of these
diseases in molecular terms. Such anal-
yses suggest that specific clinicoanatom-
ical signatures of proteinopathies can be
identified (Rohrer et al., 2010, 2011; Whit-
well et al., 2012). In particular, there
appears to be a partitioning between
pathologies that produce largely symmet-
rical versus strongly asymmetrical cere-
bral degeneration and between patholo-
gies that produce relatively localized
versus widespread degeneration at a
given disease stage. Although the
common sporadic neurodegenerative
diseases are the ultimate targets of
molecular phenotyping approaches, rare
genetic proteinopathies meanwhile
constitute crucial test cases. Rather than
mapping simply to a particular brain
network, molecular specificity in these
diseases may emerge as an interaction
between large-scale configurational and
local morphological factors (Rohrer
et al., 2011). As acknowledged by Raj
et al. (2012), complex systems may
generate relatively simple outputs; with
respect to disintegrating brain networks,
one such simple dichotomy may apply
to short- versus long-range connections.
The ‘‘small-world’’ properties of brain
networks (Bullmore and Sporns, 2009)
lead us to expect that a short-range/
long-range dichotomy should be func-
tionally meaningful, and pathways might
in turn show differential vulnerability to
molecular lesions (we outline this as a
testable hypothesis in Figure 1). ‘‘Short-
range’’ and ‘‘long-range’’ here could be
specified using anatomically grounded
methods (Modha and Singh, 2010).
Importantly, protein-specific mechanisms
might also operate at the level of events
that trigger the neurodegenerative
cascade. For example, whereas initial tar-
geting of entorhinal cortex in Alzheimer’s
disease may reflect locally enhanced
beta-amyloid-precursor protein deposi-
tion during age-related neuronal resprout-
ing (Roberts et al., 1993), progranulin-
associated neurodegeneration may be1062 Neuron 73, March 22, 2012 ª2012 Elsetriggered by an initial discrete stochastic
(e.g., vascular hypoxic) event which
becomes catastrophically amplified by
failure of synaptic repair mechanisms
(Piscopo et al., 2010).
As the work of Raj et al. (2012) and Zhou
et al. (2012) shows, graph theory gives us
a means to test specific hypotheses of
brain network disintegration. We suggest
that models of network degeneration will
need to be informed by data from a wide
variety of sources. For example, recent
work on the selective vulnerability of
network nodes to extinction under socio-
logical and ecological events (Saavedra
et al., 2011) may help generate models
for the selective targeting of the epicen-
ters identified by Zhou et al. (2012). In
addition, the power of anatomical
methods should not diminish the role of
behavioral metrics: if appropriately
generic computations can be measured,
these are likely to inform our under-
standing of network organization. Models
of human semantic processing, for
example, make relatively specific predic-
tions about permissive network architec-
ture in semantic dementia (Lambon Ralph
et al., 2010). Similar arguments favor the
use of task-based as well as task-free
fMRI to characterize damaged networks.
Empirical longitudinal data on the evolu-
tion of network disintegration are sorely
needed in order to determine the validity
of predictive models (Raj et al., 2012).
Finally, clinical neurologists and neurora-
diologists, by identifying the sometimes
counterintuitive (e.g., highly asymmetric)
profiles thrown up by particular neurode-
generative diseases, can help inform and
constrain the search for candidate
mechanisms to explain such profiles.
The power and beauty of data such as
those presented by Raj et al. (2012) and
Zhou et al. (2012) will be fully realized
if we can move beyond syndromic
disease maps to a taxonomy of protein-
based network degenerations: ‘‘molec-
ular nexopathies.’’ACKNOWLEDGMENTS
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